Anesthetic management of high grade butterfly glioma of the corpus callosum- A case report 1 2 3 4 5 **Abstract-** Glioblastoma (GBM), is an aggressive brain tumor associated with poor prognosis. The history of GBM remains unfavorable; however, recent evidence demonstrates prolonged 6 7 survival with maximal safe surgical resection followed by adjuvant radiotherapy and 8 chemotherapy. GBM typically spreads along white matter tracts. Growth and infiltration in 9 certain tracts and eloquent areas of the brain, such as the corpus callosum, can render these 10 tumors only partially resectable or unresectable.(1) GBM extending along the corpus callosum often shows a pattern of a butterfly on magnetic resonance imaging (MRI), hence the name 11 12 butterfly glioma. This case report highlights the challenges faced by anesthesiologist in providing an optimal physiological condition during intra-operative period due to its critical 13 location and its aggressive infiltrative nature. This report also focuses on how detailed pre-14 operative neurological assessment and tailored anesthetic technique can allow early assessment 15 of neurological status and a how, close communication with the surgical team can diligently 16 improve patient's outcome post-operatively. 17 18 Keywords- Glioblastoma (GBM), - Butterfly glioblastoma (bGBM), Corpus callosum, 19 Lobectomy, Cerebral Perfusion pressure (CPP), Intra-cranial pressure (ICP), Neuro-monitoring 20 21 (IONM). 22 23 **Introduction-** Butterfly glioblastoma (bGBM) is a type of glioblastoma that spreads across the 24 25 corpus callosum, affecting both sides of the brain. Previous studies have reported that it occurs in about 2.2% to 14.3% of adult glioblastoma cases. It is often linked to larger tumor size, 26 27 aggressive treatment, and poor outcome. However, it's unclear if the poor prognosis is due to the tumor's nature or the way it's treated. More research is needed to understand which factors 28 29 influence outcomes and how treatment decisions impact survival. There is no clear evidence on the best way to treat it, and it's uncertain whether general glioblastoma treatment guidelines 30 apply to this subgroup. Some studies suggest that more aggressive treatment might still help, 31 despite the poor outcomes. (2) In patients with bGBM, anesthetic management must be tailored 32 to the tumor's bi-hemispheric involvement and proximity to eloquent brain regions. Total 33 intravenous anesthesia (TIVA) using agents such as propofol and remifentanil are recommended 34 35 to facilitate neurophysiological monitoring and minimize intracranial pressure (ICP). (3)Intraoperative strategies included ICP control with mannitol and high ceiling diuretics, head 36 elevation, and hyperventilation to provide a slack brain to the surgeon. Neuro-monitoring is 37 38 essential, particularly during callosal dissection. Hemodynamic stability is critical to maintain 39 adequate cerebral perfusion while avoiding hypertensive surges. Postoperative care involves

40 close neurological monitoring for potential complications such as cerebral edema, seizures, and 41 new deficits. 42 43 Case Presentation- A 45-year-old male with no known comorbidities presented to our institution with a history of generalized involuntary jerky movements, suggestive of seizure 44 activity. He had experienced two similar episodes previously. Neuroimaging performed during 45 his initial evaluation elsewhere revealed a lesion consistent with a butterfly glioma involving the 46 corpus callosum. He was managed conservatively and referred to our center for further 47 48 evaluation and treatment. The patient also reported neurobehavioral changes over the past month, including increased talkativeness, irritability, hyperphagia, and memory disturbances. However, 49 recognition of familiar faces and names was preserved, and he remained functionally 50 independent with no impairment in daily activities. There were no motor or sensory deficits, and 51 no complaints of gait disturbance, headache, visual changes, or bowel/bladder dysfunction. 52 53 Diagnostic Assessment-On initial evaluation, the patient was hemodynamically stable with a 54 pulse rate of 80 bpm, blood pressure of 150/90 mmHg, respiratory rate of 16 breaths per minute, 55 and oxygen saturation of 99% on room air. Baseline laboratory parameters were within normal 56 limits. Given the history of poor effort tolerance, a cardiology consultation was obtained. The 57 patient was deemed fit for surgery, but classified as high cardiac risk, with a potential for 58 perioperative major adverse cardiac events (MACE). Surgical clearance was granted with 59 recommendations for enhanced perioperative cardiac and neurological surveillance and risk 60 mitigation. 61 62 Plan- Oral intubation with Controlled mechanical ventilation under TIVA with all standard ASA 63 monitors, invasive hemodynamic monitoring and IONM. 64 65 66 **Therapeutic Intervention-** The patient was categorized as ASA III, informed written consent 67 obtained for high risk procedure, outlining post-operative management, peri-operative 68 hemorrhage control if any, major adverse cardiac event risk, prolonged ICU Care, post-operative 69 70 pulmonary complications and worsening of neurological functions. Primary goal was to optimize surgical conditions, protect neurological functions, maintain CPP, minimize bleeding, potentiate 71 oncological benefits, maintain euvolemia, reduce peri-tumoral edema, maintain adequate urine-72 73 output and ensure smooth emergence to allow early neurological assessment. The patient 74 received no premedication prior to surgery. After standard ASA monitoring and pre-oxygenation for 3 minutes, anesthesia was induced with remifentanil 1 mcg/kg IV (administered slowly), 75 76 propofol 2 mg/kg IV, and rocuronium 1 mg/kg IV to facilitate tracheal intubation. The airway

was secured with an 8.5 mm flexometallic endotracheal tube. Invasive arterial and central venous access were established under aseptic precautions for continuous monitoring and volume management. A single dose of magnesium sulfate 50 mg/kg IV was administered slowly for its analgesic, neuroprotective, and anesthetic-sparing effects. Maintenance of anesthesia was achieved with TIVA using propofol at 1 mg/kg/hr. and remifentanil infusion at 0.05–0.2 mcg/kg/min, supplemented with desflurane at 0.6–0.8 MAC to ensure adequate depth while allowing neuromonitoring.(4) In anticipation of significant blood loss, tranexamic acid 1 g IV bolus was given, followed by a continuous infusion at 1 mg/kg/hr.(5) Intraoperative monitoring included invasive arterial pressure, central venous pressure, urine output, and serial blood gas analysis.(6) The surgical procedure, right frontal lobectomy, lasted 5 hours, with an estimated blood loss of approximately 700 mL, which remained within the allowable limit and did not necessitate transfusion. Fluid therapy was guided by hemodynamic parameters and urine output, maintaining euvolemia and isobalance throughout. The intraoperative course was uneventful.



Image1- Bi-hemispheric involvement (butterfly

pattern



Image-2- Mayfield pins applied and head fixed at 15-30 degrees



Image-3 – showing bi-coronal flap and frontal craniectomy.

98

97

99

100

101

102

103 104

105

106

107

108

109 110

111

112113

114

115

116

Post-operative period and follow-up- At the end of the procedure, neuromuscular blockade was reversed with sugammadex, ensuring complete recovery of neuromuscular function.(7) The remifentanil infusion was discontinued just prior to drape removal to allow controlled and hemodynamically stable emergence. The patient was extubated smoothly, with spontaneous ventilation, full orientation, and prompt responsiveness to simple verbal commands. He demonstrated intact motor function in all four limbs, enabling immediate and reliable neurological assessment. The anesthetic plan prioritized a smooth emergence to prevent bucking, straining, or coughing on the endotracheal tube, thereby minimizing the risk of intracranial hypertension, hemorrhage, or cerebral edema. Multimodal analgesia was employed using nonopioid agents (e.g., IV paracetamol) thus avoiding excessive sedation. PONV prophylaxis was administered intraoperatively to enhance patient comfort and prevent secondary complications. Comprehensive postoperative instructions were communicated to the neurosurgical and ICU teams, including the need for close neurological monitoring for potential complications such as intracranial hemorrhage, cerebral edema, pneumocephalus, seizures, and new-onset neurological deficits. Standard post-craniotomy protocols were initiated, including follow-up neuroimaging, antiepileptic therapy, and strict fluid and electrolyte management to optimize postoperative recovery and minimize secondary brain injury.

117

118

119

120

121

122123

124

125

126

127

**Discussion-** Anesthetic management of surgical resection of butterfly glioma poses unique challenges to the anesthesiologist due to the site, extent and its aggressive nature. The main goals of anesthesiologist is to optimize the surgical field, preserve neuro-physiology and ensure smooth emergence. Anesthetic management can be further divided into three phases as follows-

**Detailed pre-operative assessment**- This phase includes detailed neurological assessment like motor, sensory and cognitive dysfunctions if any. This mainly serves as a baseline value that can be compared to new onset deficits if any. There should be adequate optimization of comorbidities if any before surgery. There should be effective and clear communication with the surgeon regarding the surgical plan, duration, expected blood loss and anticipated neurological deficits if any during post-operative period.

Intra-operative management -Total Intravenous Anesthesia (TIVA) with propofol and 128 129 remifentanil is the preferred technique for craniotomies, particularly in cases involving raised intracranial pressure (ICP) or when intraoperative neuromonitoring (MEPs, SSEPs) is planned. 130 131 (8) Propofol provides reliable control over cerebral physiology by reducing (CBF) and cerebral metabolic rate of oxygen (CMRO<sub>2</sub>), contributing to ICP reduction.(9) In contrast, volatile agents 132 are associated with increased CBF and ICP and may interfere with neuromonitoring, making 133 them less ideal. TIVA offers preservation of evoked potentials, which is critical when functional 134 mapping or real-time neurophysiologic monitoring is being utilized intraoperatively. An added 135 point of interest is the ongoing investigation into propofol's potential anti-tumor properties, 136 though current evidence remains inconclusive and experimental. Remifentanil, owing to its rapid 137 onset and offset, enables precise analgesic titration with minimal residual effect, allowing for 138 smooth and prompt emergence. This is particularly advantageous for immediate post-extubation 139 neurological assessment, a key requirement in neurosurgical anesthesia. Hemodynamic goals 140 center around maintaining normotension and ensuring adequate cerebral perfusion pressure 141 (CPP). Hypotension must be avoided, as it compromises CPP. Short-acting agents such as beta-142 blockers or calcium channel blockers may be used for tight blood pressure control. Fluid therapy 143 typically favors isotonic crystalloids to maintain euvolemia, though debate continues between 144 goal-directed versus restrictive fluid strategies in neurosurgery.(10) 145

## ICP management strategies intraoperatively include:

- Head elevation to 30 degrees with the neck in a neutral, non-compressed position
- Ensuring appropriate endotracheal tube positioning to avoid endobronchial migration and increased airway pressures
- Mild hyperventilation (PaCO<sub>2</sub> ~30–35 mmHg)
- Minimal or no PEEP 151
  - Use of osmotic agents (e.g., mannitol or hypertonic saline)
- Steroids, when indicated (e.g., for vasogenic edema) 153
- In select cases, lumbar CSF drainage may be considered to further reduce ICP. 154

156

155

146

147

148

149

150

152

- Conclusion- Butterfly glioma presents significant anesthetic challenges due to its bilateral 157
- cerebral involvement and potential for raised intracranial pressure. The primary anaesthetic goals 158
- are to maintain cerebral perfusion pressure, control ICP, and ensure rapid postoperative 159
- neurological evaluation. TIVA with agents like propofol and remifentanil is preferred. 160
- Preoperative optimization, intraoperative monitoring (including invasive lines and possibly 161
- neurophysiological monitoring), and vigilant postoperative care are crucial. Multidisciplinary 162
- coordination enhances safety and outcomes. Given the poor prognosis, anaesthetic care should 163
- balance surgical goals with patient comfort, ensuring a smooth, complication-free perioperative 164
- 165 course.

## **Declaration of patient consent** 167 The authors confirm that they have gotten the necessary consent from the patient involved. In the 168 form, the patient's parent/guardian has given consent for his images and other clinical 169 170 information to be reported in the journal. The patient and his parent/guardian understand that his name and initials will not be published, and due efforts will be made to conceal his identity; 171 however, anonymity cannot be guaranteed. 172 173 Financial support/sponsorship/Funding - No funding was received for this research 174 175 **Conflicts of interest** 176 There are no conflicts of interest. 177 178 179 180 References-181 1. Opoku-Darko M, Amuah JE, Kelly JJP. Surgical Resection of Anterior and Posterior 182 Butterfly Glioblastoma. World Neurosurg. 2018 Feb 1;110:e612-20. 183 2. Bjorland LS, Dæhli Kurz K, Fluge Ø, Gilje B, Mahesparan R, Sætran H, et al. Butterfly 184 glioblastoma: Clinical characteristics, treatment strategies and outcomes in a population-185 based cohort. Neuro-Oncol Adv. 2022 July 1;4(1):vdac102. 186 187 3. Al-Rifai Z, Mulvey D. Principles of total intravenous anaesthesia: basic pharmacokinetics and model descriptions. BJA Educ. 2016 Mar 1;16(3):92-7. 188 4. Kumaria A, Hughes M, Fenner H, Moppett IK, Smith SJ. Total intravenous anaesthesia with 189 propofol and remifentanil is associated with reduction in operative time in surgery for 190 glioblastoma when compared with inhalational anaesthesia with sevoflurane. J Clin Neurosci 191 Off J Neurosurg Soc Australas. 2024 Feb;120:191–5. 192 5. Brown NJ, Wilson B, Ong V, Gendreau JL, Yang CY, Himstead AS, et al. Use of 193 194 Tranexamic Acid for Elective Resection of Intracranial Neoplasms: A Systematic Review. World Neurosurg. 2022 Apr 1;160:e209-19. 195 6. Fejleh A. Central Venous Access for Neurosurgery: PRO Subclavian Vein (SCV), CON 196 Internal Jugular Vein (IJV). 197

7. Hyland SJ, Pandya PA, Mei CJ, Yehsakul DC. Sugammadex to Facilitate Neurologic

Guidance. Cureus. 14(10):e30466.

Assessment in Severely Brain-Injured Patients: A Retrospective Analysis and Practical

198

199

200

<ul><li>201</li><li>202</li><li>203</li></ul>	8.	Ghatol D, Widrich J. Intraoperative Neurophysiological Monitoring. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 July 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK563203/
204 205	9.	Neurophysiology - an overview   ScienceDirect Topics [Internet]. [cited 2025 July 20]. Available from: https://www.sciencedirect.com/topics/neuroscience/neurophysiology
206 207	10.	Ryu T. Fluid management in patients undergoing neurosurgery. Anesth Pain Med. 2021 July 31;16(3):215–24.
208		
209		
210		
211		
212		
213		